Abstract
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis characterized by infiltration of organs by CD68+ and CD1a- lipid-laden histiocytes, including the central nervous system in more than a third of patients. Molecular analysis of ECD samples has demonstrated the prevalence of BRAF V600E mutations as high as 54%. Recently, vemurafenib became the only Food and Drug Administration-approved treatment for patients with ECD who carry the BRAF V600E mutation. However, dabrafenib has been suggested to have greater brain distribution. We describe a 44-year-old female patient treated from August of 2015 through November 2017. She presented with a 2-year history of light-headedness, fatigue, and vertigo. She was moderately dysmetric, diffusely hyperreflexic, and dysarthric in the bilateral upper and lower extremities. Her gait was wide-based. She had dysarthria and nystagmus on horizontal gaze bilaterally. Magnetic resonance imaging showed an extensive area of increased T2/fluid-attenuated inversion recovery signal in the brain stem, enhancement in the pons and midbrain, and thickening of the pituitary stalk. Positron emission tomography/computed tomography (PET/CT) and whole-body technetium Tc99m bone scintig...Continue Reading
References
Jan 18, 2011·Blood·Laurent ArnaudJulien Haroche
Mar 29, 2012·The Journal of Pharmacology and Experimental Therapeutics·Rajendar K MittapalliWilliam F Elmquist
May 23, 2012·Lancet·Gerald S FalchookRichard F Kefford
Aug 11, 2012·Blood·Julien HarocheJean-François Emile
Oct 12, 2012·The Lancet Oncology·Georgina V LongDirk Schadendorf
Dec 20, 2012·The Journal of Pharmacology and Experimental Therapeutics·Rajendar K MittapalliWilliam F Elmquist
Dec 22, 2012·Blood·Julien HarocheZahir Amoura
Jul 12, 2013·PloS One·Alastair J KingSylvie G Laquerre
May 13, 2014·Mayo Clinic Proceedings·Javier MunozRazelle Kurzrock
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Nov 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julien HarocheZahir Amoura
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Sarah J Welsh, Pippa G Corrie
May 1, 2015·BMC Research Notes·Charalampos TzoulisOlav Karsten Vintermyr
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Oct 5, 2015·The Lancet Oncology·Jean Jacques GrobCaroline Robert
Dec 13, 2016·Blood·Thierry M NordmannThomas Daikeler
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G A McArthurK Margolin
May 30, 2017·Blood Advances·Juvianee I Estrada-VerasWilliam A Gahl
Jun 9, 2017·The Lancet Oncology·Michael A DaviesGeorgina V Long
Jul 2, 2017·Blood·Fleur Cohen AubartJulien Haroche
Citations
Feb 13, 2019·Neuroradiology·Stefan WeidauerElke Hattingen
May 23, 2019·Current Oncology Reports·Matthias PapoJulien Haroche
Aug 21, 2019·The Journal of International Medical Research·Yaozhu PanHai Bai
Aug 16, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C LangR Dummer
Mar 4, 2020·Neurology. Neuroimmunology and Neuroinflammation·Macarena I de la FuenteAntonio Omuro
Feb 29, 2020·World Journal of Clinical Cases·Qin XiaMin-Zhi Mao
Jun 28, 2020·Leukemia·Francesco PegoraroAugusto Vaglio
Mar 19, 2020·Blood·Gaurav GoyalEli L Diamond
Sep 14, 2020·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Neeta Garg, Efrat Saraf Lavi
Jun 4, 2021·Survey of Ophthalmology·Menelaos KanakisIlias Georgalas
Sep 22, 2020·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Mehdi TavakoliCarlos E Mendoza-Santiesteban